Safety of Imetelstat plus ruxolitinib tablets/Jiekewei in the treatment of high-risk myelofibrosis

Research on the combination of Imetelstat (Imetelstat) and ruxolitinib tablets/ruxolitinib (Ruxolitinib) in the treatment of high-risk myelofibrosis is attracting more and more attention, especially in terms of patient safety and efficacy. This combination therapy was well tolerated and feasible in patients with myelofibrosis, particularly those who had poor response to ruxolitinib.

First of all, etelrestat is an inhibitor of telomerase and has a unique mechanism of action. Telomerase is active in many malignant tumor cells and promotes unlimited proliferation of cells. By targeting the malignant stem cell population, eltarestat can complement the effects of ruxolitinib, thereby complementing the therapeutic effects. Ruxolitinib is a JAK inhibitor that is mainly used to treat myelofibrosis, but not all patients respond well to it. Therefore, exploring the combined use of itairestat and ruxolitinib provides new clinical treatment ideas.

In the Phase 1b IMproveMF dose-escalation study (NCT05371964), 19 patients with myelofibrosis who had an inadequate response to ruxolitinib participated. This study was designed to evaluate the safety and tolerability of combination therapy with ruxolistat and ruxolitinib. Patients received intravenous etelrestat every 4 weeks while continuing to maintain a stable dose of ruxolitinib. The study explored four ascending doses of iterestat, up to 8.9 mg/kg, for at least 48 weeks, with most patients receiving treatment lasting between 12 and 15 months. This design not only ensures the evaluation of different doses but also provides the opportunity for observation of long-term efficacy.

Importantly, no dose-limiting toxicities (DLTs) were observed in any cohort of the study, meaning patients were able to receive treatment at the highest planned dose. The researchers noted that the combination was well tolerated, with only one patient experiencing grade 3/4 thrombocytopenia and no patients discontinuing treatment due to hematologic toxicity. Furthermore, no significant additive non-hematological toxicity signals were observed in the study, further supporting the feasibility of dual pathway inhibition. These data suggest that the combination of iterestat with ruxolitinib may provide a safe and effective treatment option for patients with high-risk myelofibrosis.

Additionally, the results of this study represent optimizationAn important step forward in improving treatment outcomes in patients with poor response to JAK inhibition. With the development of medical technology, more and more research has begun to focus on how to improve patients' treatment response rate, thereby improving their quality of life. By combining drugs with different mechanisms, it is expected to overcome the limitations of a single drug in the treatment process. Especially in the face of complex diseases, combination therapy can often bring better therapeutic effects.

The good display of clinical trial results lays the foundation for subsequent larger-scale clinical research. The researchers recommend continuing to evaluate the combination of iterestat and ruxolitinib to further validate its potential in patients with high-risk myelofibrosis. With the deepening of follow-up research, it is expected that more effective and safe treatment options can be provided for these patients to improve their survival rate and quality of life.

Reference materials:https://www.jakavi.com/